Business Context and Reporting Period
Company: Aadi Bioscience, Inc. (Note: Request metadata listed "Whitehawk Therapeutics, Inc.", but the filing text identifies the registrant as Aadi Bioscience, Inc.)
Filing Type: Form 8-K (Current Report)
Date: September 22, 2022
Event: Entry into a Material Definitive Agreement for a private placement of securities.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than periodic financial performance metrics (revenue, profit, or cash flow are not reported in this specific document).
- Gross Proceeds: Approximately $72.5 million (before offering expenses).
- Securities Issued:
- 3,373,526 shares of Common Stock at $12.50 per share.
- 2,426,493 Pre-Funded Warrants at $12.4999 per warrant.
- Use of Proceeds: Funding working capital and general corporate purposes.
- Management Participation: Executive officers and senior management purchased approximately $750,000 of securities.
Material Changes and Transaction Structure
The primary material change is the execution of a Securities Purchase Agreement on September 22, 2022, with qualified institutional buyers, accredited investors, and company executives. The transaction is expected to close on September 26, 2022, subject to customary conditions.
Pre-Funded Warrant Terms:
- Exercise price: $0.0001 per share.
- Immediately exercisable.
- Beneficial ownership limitation: 4.99% (increasable to 19.99% with 61 days' notice).
Registration Rights: The Company agreed to file a registration statement by October 22, 2022, to allow resale of the securities. The statement must be declared effective within 60 days of closing (or 90 days if a full SEC review occurs).
Guidance, Outlook, and Risks
Outlook: The Company intends to use the net proceeds to extend its cash runway and fund operations. The filing references a press release (Exhibit 99.1) providing an update on the cash runway, though specific runway duration is not detailed in the text provided.
Risks and Contingencies:
- Commercialization: Risks related to the commercialization of FYARRO, including reimbursement and pricing.
- Clinical Development: Uncertainties regarding clinical trial timing, enrollment, and results for additional indications (specifically TSC1 or TSC2 inactivating alterations).
- Regulatory: Risks associated with regulatory filings and approvals.
- Capital Requirements: Risks that existing capital resources may be insufficient to fund future operating expenses without additional financing.
Investor Verification Checklist
- Verify the actual closing date of the Private Placement (expected September 26, 2022) and the final net proceeds after deducting offering expenses.
- Review the attached Press Release (Exhibit 99.1) for specific details on the updated cash runway duration.
- Confirm the filing and effectiveness date of the Registration Statement required by October 22, 2022.
- Monitor subsequent filings for updates on the commercialization progress of FYARRO and the status of clinical trials.